ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa ...

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that European Urology Oncology published results of a clinical study demonstrating ...

Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...

Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...

Investigators reported 1-year disease-free survival results from patients with BCG-unresponsive papillary disease-only high-risk NMIBC in the phase 2b SunRISe-1 trial.

Xu, W. , Xing, X. and Cheng, S. (2025) Urine-Based Liquid Biopsy for Detecting Recurrence of Bladder Cancer. International ...

Johnson & Johnson's Inlexzo shows promising survival rates in BCG-unresponsive NMIBC patients. Read more here.

These findings indicate serial ctDNA monitoring could identify patients with muscle-invasive bladder cancer who benefit from adjuvant atezolizumab, while sparing patients who are persistently negative ...

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort ...

The treatment success rate for cancer patients improves when doctors detect the disease during its initial stages, because ...